Gains May Be On The Menu For Akebia Therapeutics Inc. (NASDAQ: AKBA)

Currently, there are 194.58M common shares owned by the public and among those 184.15M shares have been available to trade.

The company’s stock has a 5-day price change of -10.29% and 52.50% over the past three months. AKBA shares are trading 47.58% year to date (YTD), with the 12-month market performance up to 205.36% higher. It has a 12-month low price of $0.49 and touched a high of $2.34 over the same period. AKBA has an average intraday trading volume of 3.24 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 5.81%, 13.26%, and 43.14% respectively.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Institutional ownership of Akebia Therapeutics Inc. (NASDAQ: AKBA) shares accounts for 18.43% of the company’s 194.58M shares outstanding.

It has a market capitalization of $383.15M and a beta (3y monthly) value of 0.82. The earnings-per-share (ttm) stands at -$0.28. Price movements for the stock have been influenced by the stock’s volatility, which stands at 17.98% over the week and 11.53% over the month.

Analysts forecast that Akebia Therapeutics Inc. (AKBA) will achieve an EPS of -$0.09 for the current quarter, -$0.05 for the next quarter and -$0.23 for 2025. The lowest estimate earnings-per-share for the quarter is -$0.11 while analysts give the company a high EPS estimate of -$0.07. Comparatively, EPS for the current quarter was -$0.14 a year ago. Earnings per share for the fiscal year are expected to increase by 0.32%, and 1.92% over the next financial year.

Looking at the support for the AKBA, a number of firms have released research notes about the stock. BTIG Research stated their Buy rating for the stock in a research note on November 29, 2023, with the firm’s price target at $4. H.C. Wainwright coverage for the Akebia Therapeutics Inc. (AKBA) stock in a research note released on August 28, 2023 offered a Buy rating with a price target of $3.75. Piper Sandler was of a view on May 31, 2023 that the stock is Overweight, while Piper Sandler gave the stock Neutral rating on March 31, 2022, issuing a price target of $8- $2. Needham on their part issued Hold rating on March 31, 2022.

Most Popular

Related Posts